title: Clinical evaluation of satigrel in intermittent claudicators.
abstract: OBJECTIVE
  Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models. The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans.
  
  
  METHODS
  Prospective clinical trial with more than 4 weeks follow-up.
  
  
  METHODS
  Outpatient department of a university hospital.
  
  
  METHODS
  Ten patients with intermittent calf claudication were studied (14 limbs with obstruction, 6 limbs without obstruction, and chest wall).
  
  
  METHODS
  After giving informed consent and one week wash-out of effected agents, a 2 mg oral dose of satigrel twice daily was administered for more than 4 weeks.
  
  
  METHODS
  Transcutaneous partial pressure of oxygen (PtcO2), skin temperature, ankle pressure, and the treadmill test were determined just before therapy, after 2 and 4 weeks of satigrel therapy, and at treatment termination. The paired student's t-test was used for statistical analysis.
  
  
  RESULTS
  The PtcO2 in the foot of the ischemic leg showed a significant increase at the end of therapy compared with before therapy (p < 0.05). Skin temperature showed a significant difference in both the ischemic and healthy legs. The walking distance was also significantly extended at therapy termination.
  
  
  CONCLUSIONS
  Satigrel improved the cutaneous circulation and symptoms of patients with intermittent claudication.
authors.affiliation: First Department of Surgery, Tokyo Medical and Dental University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Iwai
authors.forename: S
authors.initials: S
authors.lastname: Qian
mesh_terms: D000328:Adult; D000368:Aged; D005080:Exercise Test; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D005229:Fatty Acids, Monounsaturated; D010975:Platelet Aggregation Inhibitors; C054678:Satigrel